Your browser doesn't support javascript.
loading
Synovial Fluid Cytokines, Chemokines and MMP Levels in Osteoarthritis Patients with Knee Pain Display a Profile Similar to Many Rheumatoid Arthritis Patients.
Meehan, Richard T; Regan, Elizabeth A; Hoffman, Eric D; Wolf, Molly L; Gill, Mary T; Crooks, James L; Parmar, Prashant J; Scheuring, Richard A; Hill, John C; Pacheco, Karin A; Knight, Vijaya.
Affiliation
  • Meehan RT; Department of Medicines, Immunology Labs and Bioinformatics National Jewish Health, Denver, CO 80206, USA.
  • Regan EA; Department of Medicines, Immunology Labs and Bioinformatics National Jewish Health, Denver, CO 80206, USA.
  • Hoffman ED; Department of Medicines, Immunology Labs and Bioinformatics National Jewish Health, Denver, CO 80206, USA.
  • Wolf ML; Department of Medicines, Immunology Labs and Bioinformatics National Jewish Health, Denver, CO 80206, USA.
  • Gill MT; Department of Medicines, Immunology Labs and Bioinformatics National Jewish Health, Denver, CO 80206, USA.
  • Crooks JL; Department of Medicines, Immunology Labs and Bioinformatics National Jewish Health, Denver, CO 80206, USA.
  • Parmar PJ; Colorado School of Public Health, CU Anschutz School of Medicine, Aurora, CO 80045, USA.
  • Scheuring RA; Department of Internal Medicine, National Jewish Health, Saint Joseph Hospital, Denver, CO 80218, USA.
  • Hill JC; Flight Medicine, NASA-Johnson Space Center, Houston, TX 77058, USA.
  • Pacheco KA; CU Sports Medicine, Department of Orthopedic Surgery, University of Colorado, Denver, CO 80222, USA.
  • Knight V; Department of Medicines, Immunology Labs and Bioinformatics National Jewish Health, Denver, CO 80206, USA.
J Clin Med ; 10(21)2021 Oct 28.
Article in En | MEDLINE | ID: mdl-34768546
BACKGROUND: There are currently no effective disease-modifying drugs to prevent cartilage loss in osteoarthritis and synovial fluid is a potentially valuable source of biomarkers to understand the pathogenesis of different types of arthritis and identify drug responsiveness. The aim of this study was to compare the differences between SF cytokines and other proteins in patients with OA (n = 21) to those with RA (n = 27) and normal knees (n = 3). METHODS: SF was obtained using ultrasound (US) guidance and an external pneumatic compression device. RA patients were categorized as active (n = 20) or controlled (n = 7) based upon SF white blood cell counts (> or <300 cells/mm3). Samples were cryopreserved and analyzed by multiplex fluorescent bead assays (Luminex). Between-group differences of 16 separate biomarker proteins were identified using ANOVA on log10-transformed concentrations with p values adjusted for multiple testing. RESULTS: Only six biomarkers were significantly higher in SF from active RA compared to OA-TNF-α, IL-1-ß IL-7, MMP-1, MMP-2, and MMP-3. Only MMP-8 levels in RA patients correlated with SF WBC counts (p < 0.0001). Among OA patients, simultaneous SF IL-4, IL-6, IL-8, and IL-15 levels were higher than serum levels, whereas MMP-8, MMP-9, and IL-18 levels were higher in serum (p < 0.05). CONCLUSION: These results support the growing evidence that OA patients have a pro-inflammatory/catabolic SF environment. SF biomarker analysis using multiplex testing and US guidance may distinguish OA phenotypes and identify treatment options based upon targeted inflammatory pathways similar to patients with RA.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline Language: En Journal: J Clin Med Year: 2021 Document type: Article Affiliation country: Estados Unidos Country of publication: Suiza

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline Language: En Journal: J Clin Med Year: 2021 Document type: Article Affiliation country: Estados Unidos Country of publication: Suiza